Press Releases

  • Jan. 27, 2021 Bioasis Announces Filing of Its Quarter and Financial Statements and MD&A for the Period Ending November 30, 2020

    GUILFORD, Conn., Jan. 27, 2021 (GLOBE NEWSWIRE) — Bioasis Technologies Inc.?(TSX.V:BTI; OTCQB:BIOAF) (the “Company” or “Bioasis”),?a?pre-clinical, research-stage?biopharmaceutical company developing its proprietary?xB3 TM?platform?technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases,?today announced… Read more »

  • Jan. 22, 2021 Bioasis Announces Stock Option Grant

    GUILFORD, Conn., Jan. 22, 2021 (GLOBE NEWSWIRE) — Bioasis Technologies, Inc. (OTCQB:BIOAF; TSX.V:BTI), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3™ platform technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need, including brain cancers and neurodegenerative… Read more »

  • Jan. 4, 2021 Bioasis to Present at Upcoming Industry Conferences

    GUILFORD, Conn., Jan. 04, 2021 (GLOBE NEWSWIRE) — Bioasis Technologies, Inc. – Bioasis Technologies Inc. (TSX.V:BTI; OTCQB:BIOAF) (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3™ platform technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high… Read more »

  • Dec. 10, 2020 Bioasis Announces Annual General Meeting Results

    GUILFORD, Conn., Dec. 10, 2020 (GLOBE NEWSWIRE) — Bioasis Technologies, Inc–Bioasis Technologies Inc. (TSX.V:BTI; OTCQB:BIOAF) (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3™ platform technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical… Read more »

  • Dec. 3, 2020 Platform Technology – Overcoming the Challenges of Drug Brain Delivery With a Novel Brain Delivery Vector

    Latest publication on Bioasis’ leading BBB drug delivery technology by Dr. Mei Mei Tian, our Head of External Research.

  • Nov. 10, 2020 Bioasis Announces Annual General Meeting Details

    GUILFORD, Conn., Nov. 10, 2020 (GLOBE NEWSWIRE) — Bioasis Technologies, Inc–Bioasis Technologies Inc. (TSX.V:BTI; OTCQB:BIOAF) (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3™ platform technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical… Read more »

  • Nov. 3, 2020 Bioasis Announces Sale of Royalty Interest in Lysosomal Storage Disorder Enzymes Being Developed Under the Chiesi Group–Bioasis Strategic Alliance to XOMA Corporation

    GUILFORD, Conn., Nov. 03, 2020 (GLOBE NEWSWIRE) — Bioasis Technologies, Inc–Bioasis Technologies Inc. (TSX.V:BTI; OTCQB:BIOAF) (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3™ platform technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical… Read more »

  • Oct. 29, 2020 Bioasis Announces Filing of Its Quarterly Financial Statements and MD&A for the Period Ending August 31, 2020

    GUILFORD, Conn., Oct. 29, 2020 (GLOBE NEWSWIRE) — Bioasis Technologies, Inc. (TSXV:BTI.V; OTCQB:BIOAF), (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 ™ platform technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need,… Read more »

  • Oct. 22, 2020 Bioasis Announces Analyst Coverage Initiated by Zacks Investment Research

    GUILFORD, Conn., Oct. 22, 2020 (GLOBE NEWSWIRE) — Bioasis Technologies, Inc. (TSXV:BTI; OTCQB:BIOAF), (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 ™ platform technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need,… Read more »

  • Oct. 20, 2020 Bioasis Announces Issuance of US Patent Relating to xB³™ Platform Technology for The Delivery of Therapeutic Agents Across the Blood-Brain Barrier

    GUILFORD, Conn., Oct. 20, 2020 (GLOBE NEWSWIRE) — Bioasis Technologies Inc. (TSX.V:BTI; OTCQB:BIOAF) (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3™ platform technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need, including brain… Read more »